Hypertension drug approved for pediatric patients

Article

Daiichi-Sankyo's agent olmesartan (Benicar) has been approved by the FDA for the treatment of hypertension in patients aged 6 to 16 years.

Daiichi-Sankyo's agent olmesartan (Benicar) has been approved by the FDA for the treatment of hypertension in patients aged 6 to 16 years.

The recommended starting dose is 10 mg once daily for patients who weigh 20 kg to less than 35 kg and 20 mg once daily for patients who weigh at least 35 kg. After 2 weeks, the dose can be increased to a maximum of 20 mg once daily in those who weigh less than 35 kg and 40 mg once daily in those who weigh at least 35 kg.

Recent Videos
Joshua Feder, MD
Zika-based therapy for metastatic neuroblastoma with Tamarah Westmoreland, MD and Joseph Mazar, PhD | Image Credit: © Nemours- © Nemours - stock.adobe.com.
Geetika Kennady, MD, FAAP
Jillian Cotter, MD
Jesse Hinckley, MD, PhD
Validating digital stethoscope for pediatric breath sounds, with Jennifer Nestor, MD
Decreasing antibiotics for acute otitis media and community acquired pneumonia, with Elysha Pifko, MD
Sensory play for children with autism, with Joshua Feder, MD
© 2025 MJH Life Sciences

All rights reserved.